A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Summary

This phase I trial evaluates the safety and feasibility of using a reduced-intensity regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin prior to a CD4+ T-cell depleted haploidentical hematopoietic cell transplant (haploHCT) for the treatment of patients with severe aplastic anemia that does not respond to treatment (refractory) or that has come back (recurrent). Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid. It may also lower the body's immune response.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Recurrent Severe Aplastic Anemia
• Refractory Severe Aplastic Anemia

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

Up to 75 years

Sex

All

Healthy volunteers

Accepted

Sponsor

City of Hope Medical Center

Last updated on ClinicalTrials.gov

January 5, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites